ASCO 2018 | KEYNOTE-042: revolutionizing lung cancer treatment with pembrolizumab monotherapy

Speaking from the American Society of Oncology (ASCO) 2018 Annual Meeting in Chicago, IL, David Carbone, MD, PhD, of Ohio State University, Athens, OH, discusses the KEYNOTE-042 trial (NCT02220894), which compared pembrolizumab with chemotherapy for lung cancer. The results were positive in favor of pembrolizumab, and potentially practice-changing, as they represent a previously unmet need for treating certain lung cancer patient groups.